Botensilimab

No colorectal cancer recurrences observed at updated median follow-up of 32.2 months in NEST-1 and 23.5 months in NEST-2 In pMMR/MSS tumors, neoadjuvant BOT+BAL achieved 59% pathologic response, including 41% major pathologic response and 32% pathologic complete response 88% of evaluable patients cleared ctDNA before surgery, with no delays to planned surgical resection Longer follow-up and immune analysis provide clinical and biological support for Agenus’ planned global Phase 3 ROBBIN trial in curative-intent MSS/pMMR colon cancer LEXINGTON, Mass.--(BUSINESS WIRE)-- $AGEN #BOT -- Agenus Inc. (Nasdaq: AGEN) , a leader in immuno-oncology innovation, today announced the peer-reviewed publication of updated results from the investigator-sponsored Phase 2 NEST trial evaluating neoadjuvant botensilimab (BOT), Agenus’ multifunctional, Fc-enhanced anti-CTLA-4 antibody, and balstilimab (BAL), Agenus’ anti-PD-1 antibody, in patients with resectable colon cancer. The manuscript, titled “Neoadjuvant botensilimab/balstilimab for localized mismatch repair proficient and deficient colon cancer: Results of the NEST phase 2 clinical trial,” was published in Clinical Cancer Research and is available here . Earlier findings from NEST were presented at the 2025 ASCO Gastrointestinal Cancers Symposium. The publication provides longer follow-up and a fuller peer-reviewed analysis of tumor responses, circulating tumor DNA (ctDNA) dynamics, disease-free follow-up and immune changes in the tumor microenvironment. At the March 31, 2026 data cutoff, no colorectal cancer recurrences had been observed, with median follow-up of 32.2 months in NEST-1 and 23.5 months in NEST-2. Among 22 mismatch repair proficient/microsatellite stable (pMMR/MSS) tumors, 59% achieved a pathologic response, including 41% with a major pathologic response and 32% with a pathologic complete response. MSS/pMMR tumors represent approximately 85% of early-stage colorectal cancers and have historically derived limited benefit from conventional immunotherapy treatment, particularly in metastatic disease. i,ii In localized colon cancer, treatment remains centered on surgery and chemotherapy, creating a need for approaches that may deepen response and reduce recurrence risk. Administering immunotherapy before surgery offers a distinct biological opportunity to activate the immune system while the primary tumor, tumor-draining lymph nodes and surrounding immune microenvironment remain intact. The publication adds peer-reviewed clinical and biological support for Agenus’ previously announced decision to prioritize BOT+BAL in earlier-stage, curative-intent MSS colon cancer. Agenus is advancing ROBBIN, a planned global randomized Phase 3 trial evaluating neoadjuvant BOT+BAL followed by standard of care versus standard of care alone in previously untreated patients with high-risk Stage II or Stage III MSS colon cancer, with event-free survival as the primary endpoint. NEST’s deep tumor regression, pre-surgical ctDNA clearance, preserved surgical timing and no observed recurrences at longer follow-up supports the clinical hypothesis ROBBIN is designed to test. “NEST provides important context for Agenus’ strategic focus on neoadjuvant BOT+BAL in MSS colon cancer,” said Steven O’Day, M.D., Chief Medical Officer of Agenus. “With longer follow-up now extending beyond two years across both NEST cohorts, the findings show BOT+BAL can generate deep tumor responses and immune activation before surgery, without delaying surgery. These results strengthen the rationale for our phase 3 ROBBIN trial and for evaluating BOT+BAL in a curative-intent setting, where the goal is to reduce the risk of recurrence and improve long-term outcomes.” NEST was a single-center, open-label, single-arm Phase 2 study that enrolled 24 eligible patients with 26 resectable colorectal tumors, including 22 pMMR/MSS tumors and four dMMR/MSI-H tumors. The study evaluated two pre-surgical treatment intervals; approximately four weeks in NEST-1 and approximately eight weeks in NEST-2. Patients in both cohorts proceeded to planned surgical resection without treatment-related delays. NEST Results Tumor responses in pMMR/MSS disease Among 22 pMMR/MSS tumors, neoadjuvant BOT+BAL achieved: 59% pathologic response rate (pOR): defined as pathologic complete response, major pathologic response or partial response 41% major pathologic response rate (MPR) : 10% or less viable tumor remaining 32% pathologic complete response rate (pCR) : no viable tumor or adjacent lymph nodes found at surgery The manuscript cites previously reported MPR rates of approximately 19% to 20%, including pCR of approximately 10%, with first-generation CTLA-4/PD-1 combination therapy in pMMR colon cancer. Cross-trial comparisons should be interpreted cautiously because of differences in study design, patient population and follow-up. Tumor responses in dMMR/MSI-H disease All four dMMR/MSI-H tumors achieved an MPR, including two pCR and two additional tumors with near-complete tumor regression of 98% and 99%. ctDNA clearance before surgery Among patients with detectable circulating tumor DNA (ctDNA) at baseline and available pre-surgical samples, 88% cleared ctDNA prior to surgery. ctDNA remained undetectable following resection in all patients evaluated. No observed recurrences at longer follow-up At the March 31, 2026 data cutoff, no colorectal cancer recurrences had been observed. Median follow-up was 32.2 months in NEST-1 and 23.5 months in NEST-2. For external context, the FOxTROT study of neoadjuvant chemotherapy reported a two-year recurrence rate of 16.9%. Cross-trial comparisons should be interpreted cautiously. Immune remodeling and activation in the tumor microenvironment Analyses of paired tumor samples showed coordinated remodeling of the tumor immune microenvironment in responding tumors, characterized by increased CD8+ T-cell infiltration, reduced FOXP3+ regulatory T cells, increased CD8+/Treg ratios and spatial reorganization of immune cells within the tumor. These findings provide biological support for BOT’s multifunctional, Fc-enhanced mechanism, which extends beyond conventional checkpoint blockade to actively remodel the immunosuppressive tumor microenvironment, and establishes a mechanistic basis for activity in historically immunotherapy-resistant pMMR/MSS tumors. Surgical feasibility and safety Patients proceeded to planned surgery without treatment-related delays. No Grade 4 treatment-related adverse events, treatment-related deaths or study discontinuations were observed. “The NEST results reinforce a major opportunity in colorectal cancer to use immunotherapy earlier, before surgery, when the primary tumor and immune system are still positioned to generate a coordinated anti-tumor response,” said Pashtoon M. Kasi, M.D., M.S., Medical Director of GI Medical Oncology at City of Hope Orange County, Rad Family Chair in Gastrointestinal Oncology, and originator of the NEST study . “For pMMR/MSS disease, where immunotherapy has historically had limited impact, the combination of pathologic responses, ctDNA clearance, no observed colorectal cancer recurrences at longer follow-up and immune remodeling is highly encouraging, particularly when viewed against historical benchmarks. These findings provide a strong foundation for continued study of neoadjuvant BOT+BAL, including NEST3, our enrolling multicenter Phase 2 investigator-sponsored study.” About the NEST and NEST 3 Studies NEST (NCT05571293 ) was an investigator-initiated, single-center, open-label Phase 2 study evaluating neoadjuvant BOT+BAL in patients with resectable colorectal cancer. The study enrolled 24 eligible patients with 26 resectable colorectal tumors, including 22 with mismatch repair proficient/microsatellite stable and four mismatch repair deficient/microsatellite instability-high tumors. Patients received neoadjuvant BOT+BAL before planned surgical resection. The primary objectives were to assess safety, feasibility and anti-tumor activity, with exploratory analyses evaluating treatment-associated changes in the tumor immune microenvironment. Agenus supported the study and provided BOT and BAL. NEST3 (NCT07595874) is an open and actively enrolling multicenter Phase 2 investigator-sponsored study evaluating neoadjuvant BOT+BAL in advanced resectable colorectal cancer. The study is sponsored by City of Hope Medical Center, led by Pashtoon M. Kasi, M.D., M.S., as overall principal investigator, and designed to enroll approximately 100 patients across 11 U.S. sites. The first patient was dosed in July 2026. NEST3 is being conducted through City of Hope’s National Clinical Trials Model, a centralized research framework designed to expand patient access to clinical trials across multiple City of Hope locations. More information is available at ClinicalTrials.gov . About Agenus Agenus is a leading immuno-oncology company targeting cancer with a comprehensive pipeline of immunological agents. The company was founded in 1994 with a mission to expand patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics) and adjuvants. Agenus has robust end-to-end development capabilities, across commercial, research and discovery. Agenus is headquartered in Lexington, MA. For more information, visit or @agenus_bio. Information that may be important to investors will be routinely posted on our website and social media channels. About Botensilimab (BOT) Botensilimab (BOT) is a human multifunctional, Fc-enhanced anti-CTLA-4 antibody designed to boost both innate and adaptive anti-tumor immune responses. Its novel design leverages mechanisms of action to extend immunotherapy benefits to “cold” tumors which generally respond poorly to standard of care or are refractory to conventional PD-1/CTLA-4 therapies and investigational therapies. Botensilimab augments immune responses across a wide range of tumor types by priming and activating T cells, reducing intratumoral regulatory T cells, activating myeloid cells and inducing durable memory responses. Approximately 1,300 patients have been treated with botensilimab and/or balstilimab in phase 1 and phase 2 clinical trials. Botensilimab alone, or in combination with Agenus’ investigational PD-1 antibody, balstilimab, has shown clinical responses across nine metastatic, late-line cancers. For more information about botensilimab trials, visit . About Balstilimab (BAL) Balstilimab is a novel, fully human monoclonal immunoglobulin G4 (IgG4) designed to block PD-1 (programmed cell death protein 1) from interacting with its ligands PD-L1 and PD-L2. It has been evaluated in more than 900 patients to date and has demonstrated clinical activity and a favorable tolerability pro several tumor types. Forward-Looking Statements This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding its botensilimab and balstilimab programs, expected regulatory timelines and filings, and any other statements containing the words "may," "believes," "expects," "anticipates," "hopes," "intends," "plans," "forecasts," "estimates," "will," “establish,” “potential,” “superiority,” “best in class,” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, among others, the factors described under the Risk Factors section of our most recent Annual Report on Form 10-K for 2025, and subsequent Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission. Agenus cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and Agenus undertakes no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. _________________________ References i Buchler T. Front Oncol. 2022;12:888181. ii Guven DC, et al. Oncologist. 2024;29(5):e580-e600. Contacts Investors 917-362-1370 | investor@agenusbio.com Media 781-674-4422 | communications@agenusbio.com

The checkpoint-inhibitor refractory cancer market is anticipated to witness significant growth and evolution throughout the forecast period, driven by the widespread adoption of immune checkpoint inhibitors, increasing awareness of resistance mechanisms, and the pressing need for next-generation therapeutic approaches such as Sitravatinib + Nivolumab (Mirati Therapeutics/Bristol Myers Squibb), TAVO + Pembrolizumab (OncoSec Medical), Botensilimab + Balstilimab (Agenus), and others, capable of overcoming resistance and restoring effective antitumor immunity in patients refractory to existing immunotherapies.. 预计在整个预测期内，免疫检查点抑制剂难治性癌症市场将实现显著增长和演变，这一趋势得益于免疫检查点抑制剂的广泛采用、对耐药机制认知的不断提升，以及对能够克服耐药性并恢复对现有免疫疗法难治患者有效抗肿瘤免疫的下一代治疗方案的迫切需求，例如Sitravatinib联合Nivolumab（Mirati Therapeutics/Bristol Myers Squibb）、TAVO联合Pembrolizumab（OncoSec Medical）、Botensilimab联合Balstilimab（Agenus）等。LAS VEGAS 拉斯维加斯, ，Aug. 19, 2026 2026年8月19日/PRNewswire/ -- Recently published Checkpoint Inhibitor Refractory Cancer Market Insights report includes a comprehensive understanding of current treatment practices, checkpoint inhibitor refractory canceremerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].. /PRNewswire/ -- 最近发布的《检查点抑制剂难治性癌症市场洞察》报告包括对当前治疗实践、检查点抑制剂难治性癌症新兴药物、各疗法的单独市场份额以及2022年至2036年的当前和预测市场规模的全面理解，并细分为主要市场[美国、欧盟四国（德国、法国、意大利和西班牙）、英国和日本]。Checkpoint Inhibitor Refractory Cancer Market Summary 免疫检查点抑制剂难治性癌症市场概况The total checkpoint inhibitor refractory cancertreatment market size is expected to grow positively by 2036 in the leading markets. 到2036年，主要市场的总体检查点抑制剂难治性癌症治疗市场规模预计将实现正增长。The United States accounted for the largest checkpoint inhibitor refractory cancertreatment market size in the 7MM in 2025, compared to other major markets, including the EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan. 2025年，在七大主要市场（7MM）中，美国占据了最大的检查点抑制剂难治性癌症治疗市场规模，其他主要市场包括欧盟四国（德国、法国、意大利和西班牙）、英国和日本。In many cancers such as melanoma, NSCLC, renal cell carcinoma, urothelial carcinoma, and head and neck cancers, approximately 在黑色素瘤、非小细胞肺癌、肾细胞癌、尿路上皮癌和头颈部癌症等多种癌症中，大约40–60% 40–60%of patients experience primary resistance to PD-1/PD-L1 inhibitor therapy, while a substantial proportion of initial responders eventually develop acquired resistance and disease progression. 部分患者对PD-1/PD-L1抑制剂治疗产生原发性耐药，而相当一部分初始应答者最终会发展为获得性耐药并出现疾病进展。Leading checkpoint inhibitor refractory cancer companies, such as 领先的对检查点抑制剂耐药的癌症公司，例如Mirati Therapeutics, Bristol Myers Squibb, OncoSec Medical, Agenus, Compass Therapeutics, TILT Biotherapeutics, ImCheck Therapeutics, Phanes Therapeutics, OncoC4, CanBas Co. Ltd., Sumitomo Pharma America, Inc., Mirati Therapeutics、百时美施贵宝、OncoSec Medical、Agenus、Compass Therapeutics、TILT Biotherapeutics、ImCheck Therapeutics、Phanes Therapeutics、OncoC4、CanBas Co. Ltd.、Sumitomo Pharma America, Inc.，and others, are developing new checkpoint inhibitor refractory cancer treatmentdrugs that can be available in the checkpoint inhibitor refractory cancer market in the coming years. 以及其他公司，正在开发新的针对检查点抑制剂耐药性癌症的治疗药物，这些药物有望在未来几年内进入检查点抑制剂耐药性癌症市场。The promising checkpoint inhibitor refractory cancer therapiesin clinical trials include 临床试验中前景良好的针对检查点抑制剂难治性癌症的疗法包括Sitravatinib + Nivolumab, TAVO + Pembrolizumab, Botensilimab + Balstilimab, CTL-002, TILT-123, ICT01, Mavrostobart (PT199), ONC-841, CBP 501, SMP3124, 西特拉瓦替尼 + 纳武利尤单抗，TAVO + 帕博利珠单抗，Botensilimab + Balstilimab，CTL-002，TILT-123，ICT01，Mavrostobart (PT199)，ONC-841，CBP 501，SMP3124，and others. 以及其他。Discover new treatment options for checkpoint inhibitor refractory cancer @ 探索针对检查点抑制剂难治性癌症的新治疗方案 @https://www.delveinsight.com/report-store/checkpoint-inhibitor-refractory-cancer-market https://www.delveinsight.com/report-store/checkpoint-inhibitor-refractory-cancer-marketKey Factors Driving the Growth of the Checkpoint Inhibitor Refractory Cancer Market 推动检查点抑制剂难治性癌症市场增长的关键因素Rising Incidence of Checkpoint Inhibitor Resistance: 检查点抑制剂耐药性发生率上升：A growing proportion of cancer patients either fail to respond to immune checkpoint inhibitors or develop resistance after an initial response. This increasing unmet clinical need is driving demand for novel therapies specifically designed to overcome refractory disease. 越来越多的癌症患者对免疫检查点抑制剂无应答，或在初始应答后产生耐药性。这一日益增长的未满足临床需求正推动市场对专门用于克服难治性疾病的新型疗法的需求。Expanding Use of Immune Checkpoint Inhibitors: 免疫检查点抑制剂应用的扩展：The widespread adoption of checkpoint inhibitors across multiple tumor types has significantly increased the population of patients who may eventually develop treatment resistance. This expanding patient pool is creating substantial market opportunities for next-generation therapeutic approaches. 检查点抑制剂在多种肿瘤类型中的广泛应用，显著增加了最终可能出现治疗耐药性的患者群体。这一不断扩大的患者群体为下一代治疗方法创造了巨大的市场机会。Robust Pipeline of Innovative Therapies: 稳健的创新疗法管线：Pharmaceutical and biotechnology companies are actively developing novel immunotherapies, targeted therapies, bispecific antibodies, antibody-drug conjugates (ADCs), cell therapies, and combination regimens aimed at restoring antitumor immune responses in refractory patients. 制药和生物技术公司正在积极开发新型免疫疗法、靶向疗法、双特异性抗体、抗体药物偶联物（ADC）、细胞疗法以及联合治疗方案，旨在恢复难治性患者的抗肿瘤免疫反应。Growing Focus on Combination Treatment Strategies: 日益关注联合治疗策略：Combination therapies involving checkpoint inhibitors with targeted agents, chemotherapy, radiotherapy, cytokines, or other immunotherapies are being extensively evaluated to improve response rates and overcome immune resistance, supporting market expansion. 涉及检查点抑制剂与靶向药物、化疗、放疗、细胞因子或其他免疫疗法的联合疗法正在被广泛评估，以提高响应率并克服免疫耐药性，从而支持市场扩张。Increasing Clinical Trial Activity: 临床试验活动日益增加：A surge in clinical trials investigating novel therapies including 临床试验激增，旨在研究包括Sitravatinib + Nivolumab 西特拉伐替尼 + 纳武利尤单抗(Mirati Therapeutics/Bristol Myers Squibb), （Mirati Therapeutics/百时美施贵宝）TAVO + Pembrolizumab TAVO + 帕博利珠单抗(OncoSec Medical), （OncoSec Medical）Botensilimab + Balstilimab 博特西利单抗 + 巴替利单抗(Agenus), （Agenus），CTL-002 CTL-002(Compass Therapeutics), (康帕斯治疗公司),TILT-123 TILT-123(TILT Biotherapeutics), (TILT 生物治疗公司)ICT01 ICT01(ImCheck Therapeutics), (ImCheck Therapeutics)，Mavrostobart (PT199) 马夫罗斯托巴特 (PT199)(Phanes Therapeutics), and others, is strengthening the future product pipeline. Positive clinical data are expected to drive regulatory approvals and commercial growth. （Phanes Therapeutics）等公司正在加强未来的产品管线。积极的临床数据有望推动监管审批和商业增长。Sadaf Javed, Functional Head of Forecasting & Analytics at DelveInsight, said that the Botensilimab plus balstilimab may achieve particularly strong uptake if ongoing registrational studies continue to demonstrate meaningful survival benefits in microsatellite-stable colorectal cancer and other immunotherapy-resistant tumors.. DelveInsight 预测与分析功能负责人 Sadaf Javed 表示，如果正在进行的注册研究继续证明 botensilimab 联合 balstilimab 在微卫星稳定型结直肠癌和其他免疫治疗耐药肿瘤中具有显著的生存获益，则该组合疗法可能会实现特别强劲的市场渗透。Checkpoint Inhibitor Refractory Cancer Market Analysis 检查点抑制剂难治性癌症市场分析Management of checkpoint inhibitor-refractory cancer is centered on overcoming mechanisms of immune resistance, reactivating antitumor immunity, delaying disease progression, extending survival, and enhancing patients' quality of life. checkpoint抑制剂难治性癌症的管理核心在于克服免疫耐药机制、重新激活抗肿瘤免疫、延缓疾病进展、延长生存期以及提高患者的生活质量。Treatment generally requires a multidisciplinary strategy that integrates immunotherapy-based approaches, targeted therapies, adoptive cell therapies, chemotherapy, radiotherapy, and biomarker-driven treatment selection. Therapeutic decisions are influenced by several factors, including tumor histology, previous response to immune checkpoint inhibitors, molecular alterations, disease burden, patient performance status, and the specific biological mechanisms responsible for immune resistance.. 治疗通常需要采取多学科策略，整合基于免疫疗法的方法、靶向治疗、过继细胞治疗、化疗、放疗以及基于生物标志物的治疗选择。治疗决策受多种因素影响，包括肿瘤组织学特征、既往对免疫检查点抑制剂的反应、分子改变、疾病负荷、患者体能状态以及导致免疫耐药的具体生物学机制。Because refractory disease is associated with poor clinical outcomes, prompt recognition of treatment resistance and timely initiation of appropriate therapies are essential for optimizing patient care. 由于难治性疾病与不良临床结局相关，及时识别治疗耐药并适时启动适当的治疗方案对于优化患者管理至关重要。Existing treatment approaches differ across tumor types and may involve 现有的治疗方法因肿瘤类型而异，可能涉及alternative immune checkpoint inhibitor combinations, targeted therapies, chemotherapy, radiotherapy, tumor-infiltrating lymphocyte (TIL) therapy 替代性免疫检查点抑制剂联合疗法、靶向治疗、化疗、放疗、肿瘤浸润淋巴细胞（TIL）疗法, or participation in clinical trials evaluating novel immuno-oncology agents. ，或参与评估新型免疫肿瘤药物的临床试验。Recent therapeutic advances, including the approval of 包括获批在内的近期治疗进展，Lifileucel (AMTAGVI) 利福昔明（AMTAGVI）, have highlighted the promise of adoptive cell therapy for patients with advanced melanoma whose disease progresses following checkpoint inhibitor therapy. ，凸显了过继性细胞疗法在检查点抑制剂治疗后疾病进展的晚期黑色素瘤患者中的应用前景。Similarly, targeted therapies such as 同样，靶向疗法例如Erdafitinib (BALVERSA) 厄达替尼（BALVERSA）, along with combination immunotherapy regimens, are increasingly being used in selected patients based on molecular and genomic characteristics. ，以及联合免疫治疗方案，正根据分子和基因组特征在特定患者中日益广泛地应用。Nevertheless, effective treatment options remain limited for many individuals with primary or acquired resistance to immune checkpoint inhibitors, and durable long-term responses continue to be a significant unmet need. 然而，对于许多对免疫检查点抑制剂产生原发性或获得性耐药的患者而言，有效的治疗选择仍然有限，而持久的长期缓解依然是一个显著未满足的临床需求。As a result, the therapeutic landscape is increasingly shifting toward next-generation immunotherapies and innovative strategies designed to overcome immune resistance. Several investigational therapies, including 因此，治疗格局正日益向旨在克服免疫耐受的下一代免疫疗法和创新策略转变。多种在研疗法，包括Botensilimab + Balstilimab, Domvanalimab + Zimberelimab, Sitravatinib + Nivolumab, Bemcentinib + Pembrolizumab, Visugromab (CTL-002), CUE-101, CMP-001 + Nivolumab, and TAVO + Pembrolizumab Botensilimab + Balstilimab，Domvanalimab + Zimberelimab，Sitravatinib + Nivolumab，Bemcentinib + Pembrolizumab，Visugromab (CTL-002)，CUE-101，CMP-001 + Nivolumab，以及 TAVO + Pembrolizumab, are currently being evaluated for their ability to enhance T-cell activation, reverse immune suppression, remodel the tumor microenvironment, and improve clinical responses in patients with checkpoint inhibitor-refractory cancers. ，目前正在评估其在增强T细胞活化、逆转免疫抑制、重塑肿瘤微环境以及改善对检查点抑制剂难治性癌症患者临床反应方面的能力。By targeting the biological mechanisms responsible for treatment resistance, these emerging therapies have the potential to transform future management strategies and achieve more durable clinical outcomes. 通过靶向导致治疗耐药的生物机制，这些新兴疗法有望变革未来的管理策略，实现更持久的临床疗效。Checkpoint Inhibitor Refractory Cancer Competitive Landscape 检查点抑制剂难治性癌症竞争格局Some of the checkpoint inhibitor refractory cancer drugs under development include 正在开发的部分对检查点抑制剂耐药的癌症药物包括Sitravatinib + Nivolumab 西特拉瓦替尼 + 纳武利尤单抗(Mirati Therapeutics/Bristol Myers Squibb), （Mirati Therapeutics/百时美施贵宝）TAVO + Pembrolizumab TAVO + 帕博利珠单抗(OncoSec Medical), (OncoSec Medical),Botensilimab + Balstilimab Botensilimab + Balstilimab(Agenus), （Agenus），CTL-002 CTL-002(Compass Therapeutics), (康帕斯治疗公司),TILT-123 TILT-123(TILT Biotherapeutics), (TILT 生物治疗公司),ICT01 ICT01(ImCheck Therapeutics), (ImCheck Therapeutics)Mavrostobart (PT199) 马夫罗斯托巴特 (PT199)(Phanes Therapeutics), (法内斯治疗公司),ONC-841 ONC-841(OncoC4), (OncoC4)，CBP 501 CBP 501(CanBas Co. Ltd.), （CanBas有限公司）SMP3124 SMP3124(Sumitomo Pharma America, Inc.), and others. （住友制药美国公司）及其他。Sitravatinib 西特拉瓦替尼is an orally administered, spectrum-selective tyrosine kinase inhibitor that targets the TAM receptor family (TYRO3, AXL, and MERTK), along with VEGFR and MET signaling pathways. It is designed to remodel the immunosuppressive tumor microenvironment and restore responsiveness to immune checkpoint inhibitors. 是一种口服的、谱选择性的酪氨酸激酶抑制剂，靶向TAM受体家族（TYRO3、AXL和MERTK）以及VEGFR和MET信号通路。它旨在重塑免疫抑制性肿瘤微环境，并恢复对免疫检查点抑制剂的反应性。In combination with nivolumab, sitravatinib is being evaluated for the treatment of advanced solid tumors that have progressed despite prior checkpoint inhibitor therapy, with a primary focus on non-small cell lung cancer (NSCLC) and renal cell carcinoma (RCC). Clinical findings suggest that the combination may help overcome acquired resistance to PD-1 inhibitors by reducing immunosuppressive myeloid-cell populations while enhancing T-cell-mediated antitumor activity. 西曲替尼联合纳武利尤单抗正在接受评估，用于治疗既往接受过免疫检查点抑制剂治疗后仍进展的晚期实体瘤，主要聚焦于非小细胞肺癌（NSCLC）和肾细胞癌（RCC）。临床研究表明，该联合疗法可能通过减少免疫抑制性髓系细胞群，同时增强T细胞介导的抗肿瘤活性，从而帮助克服对PD-1抑制剂的获得性耐药。Updated Phase II results presented in April 2025 demonstrated continued clinical activity of sitravatinib plus nivolumab in patients with metastatic clear-cell RCC who had experienced disease progression following previous immune checkpoint inhibitor treatment, highlighting its potential in checkpoint inhibitor-refractory disease.. 2025年4月公布的最新II期研究结果显示，西地尼布联合纳武利尤单抗在既往接受免疫检查点抑制剂治疗后出现疾病进展的转移性透明细胞肾细胞癌患者中持续展现出临床活性，凸显了其在检查点抑制剂难治性疾病中的潜力。OncoSec Medical's Tavokinogene telseplasmid (TAVO) OncoSec Medical 公司的塔沃基因特尔斯质粒（TAVO）is an investigational intratumoral IL-12 plasmid immunotherapy administered through electroporation to induce localized cytokine expression and strengthen antitumor immune responses. Combined with pembrolizumab, TAVO aims to transform immunologically 'cold' tumors into 'hot' tumors, thereby improving their responsiveness to PD-1 inhibition. 是一种研究中的瘤内IL-12质粒免疫疗法，通过电穿孔给药以诱导局部细胞因子表达并增强抗肿瘤免疫反应。TAVO与帕博利珠单抗联用，旨在将免疫学上的“冷”肿瘤转化为“热”肿瘤，从而提高其对PD-1抑制的响应性。This therapeutic approach has been investigated across several checkpoint inhibitor-resistant cancers, including metastatic melanoma and triple-negative breast cancer (TNBC). The FDA has granted TAVO Fast Track designation for metastatic melanoma that has progressed after prior anti-PD-1 therapy, while ongoing clinical studies continue to assess its potential to restore sensitivity in tumors that have become resistant to checkpoint blockade.. 该疗法已在多种对免疫检查点抑制剂耐药的癌症中进行了研究，包括转移性黑色素瘤和三阴性乳腺癌（TNBC）。美国食品药品监督管理局（FDA）已授予TAVO快速通道资格，用于既往接受抗PD-1治疗后进展的转移性黑色素瘤；同时，正在进行的临床研究继续评估其在恢复对免疫检查点阻断耐药的肿瘤敏感性方面的潜力。ImCheck Therapeutics' ICT01 ImCheck Therapeutics 公司的 ICT01is a humanized monoclonal antibody targeting BTN3A (CD277) that selectively activates γ9δ2 T cells, key immune cells involved in the surveillance and elimination of malignant and infected cells. The three BTN3A isoforms recognized by ICT01 are highly expressed across a broad range of solid tumors, including melanoma, urothelial, colorectal, ovarian, pancreatic, and lung cancers, as well as hematologic malignancies such as leukemia and lymphoma. 是一种靶向BTN3A（CD277）的人源化单克隆抗体，能够选择性激活γ9δ2 T细胞，这类关键免疫细胞参与对恶性细胞和感染细胞的监视与清除。ICT01识别的三种BTN3A亚型在多种实体瘤中高度表达，包括黑色素瘤、尿路上皮癌、结直肠癌、卵巢癌、胰腺癌和肺癌，以及在白血病和淋巴瘤等血液系统恶性肿瘤中也高度表达。BTN3A is also present on innate and adaptive immune cells, including γδ T cells, NK cells, T cells, and B cells, and plays a pivotal role in initiating γ9δ2 T-cell-mediated antitumor immunity.. BTN3A也存在于先天性和适应性免疫细胞上，包括γδ T细胞、NK细胞、T细胞和B细胞，并在启动γ9δ2 T细胞介导的抗肿瘤免疫中发挥关键作用。Data presented at major oncology conferences, including AACR, ASCO, ASH, ESMO, and SITC, have shown that ICT01 selectively activates circulating γ9δ2 T cells, promoting their migration from the bloodstream into tumor tissue. This activation initiates a broader immune response through the release of pro-inflammatory cytokines, such as IFN-γ and TNF-α, thereby amplifying antitumor immune activity. 在包括美国癌症研究协会（AACR）、美国临床肿瘤学会（ASCO）、美国血液学会（ASH）、欧洲肿瘤内科学会（ESMO）和癌症免疫治疗学会（SITC）在内的主要肿瘤学会议上公布的数据显示，ICT01 能够选择性激活循环中的 γ9δ2 T 细胞，促进其从血液迁移至肿瘤组织。这种激活通过释放干扰素-γ（IFN-γ）和肿瘤坏死因子-α（TNF-α）等促炎细胞因子，引发更广泛的免疫反应，从而增强抗肿瘤免疫活性。Clinical studies have demonstrated antitumor efficacy across multiple cancer indications. In July 2025, ICT01 received Orphan Drug Designation from both the U.S. FDA and the European Medicines Agency (EMA) for the treatment of acute myeloid leukemia (AML), further supporting its development in hematologic malignancies.. 临床研究已证实ICT01在多种癌症适应症中具有抗肿瘤疗效。2025年7月，ICT01获得美国食品药品监督管理局（FDA）和欧洲药品管理局（EMA）授予的孤儿药资格认定，用于治疗急性髓系白血病（AML），这进一步支持了其在血液系统恶性肿瘤中的开发。The anticipated launch of these emerging therapies are poised to transform the checkpoint inhibitor refractory cancermarket landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the checkpoint inhibitor refractory cancermarket landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.. 这些新兴疗法的预期上市将在未来几年内重塑对检查点抑制剂耐药的癌症市场格局。随着这些前沿疗法不断成熟并获得监管批准，它们有望重塑该市场格局，提供新的护理标准，并为医疗创新和经济增长释放机遇。Discover more about which pipeline drugs could transform checkpoint inhibitor refractory cancer treatment @ 了解更多关于哪些在研药物可能变革对检查点抑制剂耐药的癌症治疗 @Checkpoint Inhibitor Refractory Cancer Therapeutics Market 检查点抑制剂难治性癌症治疗市场Recent Developments in the Checkpoint Inhibitor Refractory Cancer Market 检查点抑制剂难治性癌症市场的最新进展In 在May 2026, Agenus 2026年5月，Agenuspresented Phase II data for botensilimab plus balstilimab (BOT+BAL) in advanced cutaneous melanoma refractory or resistant to prior anti–PD-(L) 1 therapy, including patients previously exposed to CTLA-4 inhibitors. The findings, presented at the ASCO Annual Meeting 2026, highlighted the continued clinical activity of the combination in a heavily pretreated population with limited treatment options, further supporting its development in checkpoint inhibitor-refractory cancers. 公布了botensilimab联合balstilimab（BOT+BAL）在既往抗PD-(L)1治疗难治或耐药的晚期皮肤黑色素瘤中的II期数据，其中包括此前曾接受过CTLA-4抑制剂治疗的患者。这些在2026年美国临床肿瘤学会（ASCO）年会上公布的研究结果，突显了该联合方案在经过大量前期治疗且治疗选择有限的患者群体中持续的临床活性，进一步支持其在检查点抑制剂难治性癌症中的开发。In 在April 2026, Agenus 2026年4月，Agenusreported positive Phase II data evaluating botensilimab and balstilimab in combination with agenT-797 in patients with PD-1-refractory gastroesophageal adenocarcinoma. The study demonstrated a disease control rate of 77% and durable survival outcomes in heavily pretreated patients, supporting the potential of multi-mechanistic immunotherapy approaches to overcome resistance to prior checkpoint inhibition.. 公布了评估botensilimab和balstilimab联合agenT-797治疗PD-1难治性胃食管腺癌患者的积极II期临床试验数据。该研究在既往接受过大量治疗的患者中显示出77%的疾病控制率以及持久的生存获益，支持了多机制免疫疗法克服既往检查点抑制剂耐药性的潜力。In 在March 2026, Agenus 2026年3月，Agenusannounced that preliminary results from an investigator-sponsored study evaluating botensilimab plus balstilimab in first-line MSS metastatic colorectal cancer would be presented at the AACR Annual Meeting 2026. The study explores a chemotherapy-sparing immunotherapy strategy aimed at improving outcomes in a patient population historically unresponsive to conventional checkpoint inhibitors.. 宣布将在2026年美国癌症研究协会（AACR）年会上公布一项由研究者发起的评估botensilimab联合balstilimab一线治疗微卫星稳定（MSS）转移性结直肠癌的初步研究结果。该研究探索了一种旨在改善传统检查点抑制剂历来无效的患者群体预后的免化疗免疫治疗策略。Checkpoint Inhibitor Refractory Cancer Epidemiology Segmentation 免疫检查点抑制剂难治性癌症的流行病学细分The checkpoint inhibitor refractory cancerepidemiology section provides insights into the historical and current checkpoint inhibitor refractory cancerpatient pool and forecasted trends for the leading markets. The 检查点抑制剂难治性癌症流行病学部分提供了对主要市场历史和当前检查点抑制剂难治性癌症患者群体及预测趋势的洞察。United States 美国is expected to account for the largest share of the checkpoint-inhibitor refractory cancer population across the 7MM during the forecast period, driven by high immunotherapy utilization rates, broad access to innovative oncology treatments, and a large cancer patient population. 预计在预测期内，它将占7MM国家中 checkpoint 抑制剂难治性癌症人群的最大份额，这得益于高免疫治疗利用率、对创新肿瘤疗法的广泛可及性以及庞大的癌症患者群体。The checkpoint inhibitor refractory cancertreatment market reportproffers epidemiological analysis for the study period 2022–2036 in the leading markets, segmented into: 《检查点抑制剂难治性癌症治疗市场报告》提供了2022年至2036年研究期间主要市场的流行病学分析，细分如下：Total Incidence Cases of Cancer by Types 按类型划分的癌症总发病病例数Total Checkpoint-Inhibitor Treated Patients 接受检查点抑制剂治疗的总患者数Checkpoint-Inhibitor Refractory Patients 对检查点抑制剂耐药的患者Checkpoint Inhibitor Refractory Cancer Market Report Metrics 检查点抑制剂难治性癌症市场报告指标Details 详情Study Period 学习阶段2022–2036 2022–2036Coverage 覆盖范围7MM [The United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]. 700万 [美国、欧盟四国（德国、法国、意大利和西班牙）、英国和日本]。Checkpoint Inhibitor Refractory Cancer Epidemiology Segmentation 检查点抑制剂难治性癌症的流行病学细分Total Incidence Cases of Cancer by Types, Total Checkpoint-Inhibitor Treated Patients, and Checkpoint-Inhibitor Refractory Patients 按类型划分的癌症总发病病例数、接受检查点抑制剂治疗的患者总数以及对检查点抑制剂耐药的患者Key Checkpoint Inhibitor Refractory Cancer Companies 关键检查点抑制剂难治性癌症公司Mirati Therapeutics, Bristol Myers Squibb, OncoSec Medical, Agenus, Compass Therapeutics, TILT Biotherapeutics, ImCheck Therapeutics, Phanes Therapeutics, OncoC4, CanBas Co. Ltd., Sumitomo Pharma America, Inc., Iovance Biotherapeutics, and others Mirati Therapeutics、百时美施贵宝、OncoSec Medical、Agenus、Compass Therapeutics、TILT Biotherapeutics、ImCheck Therapeutics、Phanes Therapeutics、OncoC4、CanBas Co. Ltd.、Sumitomo Pharma America, Inc.、Iovance Biotherapeutics 等KeyCheckpoint Inhibitor Refractory CancerTherapies 关键检查点抑制剂难治性癌症疗法Sitravatinib + Nivolumab, TAVO + Pembrolizumab, Botensilimab + Balstilimab, CTL-002, TILT-123, ICT01, Mavrostobart (PT199), ONC-841, CBP 501, SMP3124, AMTAGVI, and others 西特拉伐替尼 + 纳武利尤单抗、TAVO + 帕博利珠单抗、Botensilimab + Balstilimab、CTL-002、TILT-123、ICT01、Mavrostobart（PT199）、ONC-841、CBP 501、SMP3124、AMTAGVI 等Scope of the 范围Checkpoint Inhibitor Refractory Cancer 免疫检查点抑制剂难治性癌症Market Report 市场报告Checkpoint Inhibitor Refractory Cancer Patient Population Forecast 免疫检查点抑制剂难治性癌症患者人群预测Checkpoint Inhibitor Refractory Cancer Therapeutics Market Size 检查点抑制剂难治性癌症治疗市场规模Checkpoint Inhibitor Refractory Cancer Pipeline Analysis 检查点抑制剂难治性癌症管线分析Checkpoint Inhibitor Refractory Cancer Market Size and Trends 免疫检查点抑制剂难治性癌症市场规模及趋势Checkpoint Inhibitor Refractory Cancer Market Opportunity 免疫检查点抑制剂难治性癌症市场机遇Checkpoint Inhibitor Refractory Cancer Market Unmet Needs 检查点抑制剂难治性癌症市场的未满足需求KOL's Views on Checkpoint Inhibitor Refractory Cancer 关键意见领袖对检查点抑制剂难治性癌症的观点Checkpoint Inhibitor Refractory Cancer Market Access and Reimbursement 免疫检查点抑制剂难治性癌症的市场准入与报销Download the report to understand the top emerging checkpoint inhibitor refractory cancer therapies @ 下载报告以了解顶尖的新兴免疫检查点抑制剂难治性癌症疗法 @Checkpoint Inhibitor Refractory Cancer Clinical Trials checkpoint抑制剂难治性癌症临床试验Table of Contents 目录1 1Checkpoint Inhibitor Refractory Cancer Market Key Insights 免疫检查点抑制剂难治性癌症市场关键洞察2 2Checkpoint Inhibitor Refractory Cancer Market Report Introduction 检查点抑制剂难治性癌症市场报告引言3 3Executive Summary 执行摘要4 4Key Events 关键事件5 5Epidemiology and Market Forecast Methodology 流行病学与市场预测方法论6 6Checkpoint-Inhibitor Refractory Cancer Market Overview at a Glance 免疫检查点抑制剂难治性癌症市场概览6.1 6.1Clinical Landscape Analysis (By Phase, Molecule Type, and RoA) 临床格局分析（按阶段、分子类型和给药途径）6.2 6.2Market Share (%) Distribution of Checkpoint-Inhibitor Refractory Cancer By Therapies in the 7MM, in 2025 2025年七大主要市场（7MM）中按疗法划分的检查点抑制剂难治性癌症市场份额（%）分布6.3 6.3Market Share (%) Distribution of Checkpoint-Inhibitor Refractory Cancer By Therapies in the 7MM, in 2036 2036年七大主要市场（7MM）中按疗法划分的检查点抑制剂难治性癌症市场份额（%）分布7 7Disease Background and Overview of Checkpoint-Inhibitor Refractory Cancer 疾病背景及免疫检查点抑制剂难治性癌症概述7.1 7.1Introduction 简介7.2 7.2Types 类型7.3 7.3Symptoms 症状7.4 7.4Causes 原因7.5 7.5Pathophysiology 病理生理学7.6 7.6Diagnosis 诊断7.7 7.7Treatment 治疗8 8Epidemiology and Patient Population of Checkpoint-Inhibitor Refractory Cancer 检查点抑制剂难治性癌症的流行病学与患者人群8.1 8.1Key Findings 主要发现8.2 8.2Assumptions and Rationale 假设与理由8.3 8.3Total Incident Cases of Checkpoint-Inhibitor Refractory Cancer in the 7MM 七国市场（7MM）中检查点抑制剂难治性癌症的总发病病例数8.4 8.4The United States 美国8.4.1 8.4.1Total Incidence by tumor type in the United States 美国按肿瘤类型划分的总发病率8.4.2 8.4.2Total Checkpoint-Inhibitor treated patients in the United States 美国接受检查点抑制剂治疗的患者总数8.4.3 8.4.3Checkpoint-Inhibitor refractory patients in the United States 美国对检查点抑制剂难治的患者8.5 8.5EU4 and the UK 欧盟四国与英国8.6 8.6Japan 日本9 9Patient Journey of Checkpoint-Inhibitor Refractory Cancer 检查点抑制剂难治性癌症的患者诊疗路径List to be continued in the report… 列表中将在报告中继续……10 10Emerging Drugs 新兴药物10.1 10.1Emerging Competitive Landscape of Checkpoint-Inhibitor Refractory Cancer 检查点抑制剂难治性癌症的新兴竞争格局10.2 10.2Sitravatinib + Nivolumab: Mirati Therapeutics/Bristol Myers Squibb 西特拉伐替尼 + 纳武利尤单抗：Mirati Therapeutics/百时美施贵宝10.2.1 10.2.1Drug Description 药物说明10.2.2 10.2.2Other Developmental Activity 其他发展性活动10.2.3 10.2.3Clinical Development 临床开发10.2.3.1 10.2.3.1Clinical Trials Information 临床试验信息10.2.4 10.2.4Analyst Views 分析师观点10.3 10.3TAVO + Pembrolizumab: OncoSec Medical TAVO + 帕博利珠单抗：OncoSec MedicalList to be continued in the report… 列表中待继续的内容将在报告中呈现……11 十一Checkpoint-Inhibitor Refractory Cancer: 7MM Analysis 检查点抑制剂难治性癌症：7MM分析11.1 11.1Key Findings 主要发现11.2 11.2Market Outlook of Checkpoint-Inhibitor Refractory Cancer 检查点抑制剂难治性癌症的市场前景11.3 11.3Key Checkpoint Inhibitor Refractory Cancer Market Forecast Assumptions 关键检查点抑制剂难治性癌症市场预测假设11.4 11.4Conjoint Analysis of Checkpoint-Inhibitor Refractory Cancer 检查点抑制剂难治性癌症的联合分析11.5 11.5Total Market Size of Checkpoint-Inhibitor Refractory Cancer in the 7MM 七大主要市场（7MM）中免疫检查点抑制剂难治性癌症的总体市场规模11.6 11.6Total Market Size of Checkpoint-Inhibitor Refractory Cancer by Therapies in the 7MM 七大主要市场中按疗法划分的检查点抑制剂难治性癌症总市场规模11.7 11.7The United States Checkpoint Inhibitor Refractory Cancer Market 美国检查点抑制剂难治性癌症市场11.7.1 11.7.1Total Market Size of Checkpoint-Inhibitor Refractory Cancer in the United States 美国检查点抑制剂难治性癌症的总体市场规模11.7.2 11.7.2Total Market Size of Checkpoint-Inhibitor Refractory Cancer by Therapies in the United States 美国按疗法划分的检查点抑制剂难治性癌症总市场规模11.8 11.8EU4 and the UK Checkpoint Inhibitor Refractory Cancer Market 欧盟四国及英国检查点抑制剂难治性癌症市场11.9 11.9Japan Checkpoint Inhibitor Refractory Cancer Market 日本检查点抑制剂难治性癌症市场12 十二Unmet Needs of Checkpoint-Inhibitor Refractory Cancer 检查点抑制剂难治性癌症的未满足需求13 十三SWOT Analysis of Checkpoint-Inhibitor Refractory Cancer 检查点抑制剂难治性癌症的SWOT分析14 14KOL Views of Checkpoint-Inhibitor Refractory Cancer 关键意见领袖对 checkpoint 抑制剂难治性癌症的观点15 十五Market Access and Reimbursement of Checkpoint-Inhibitor Refractory Cancer 检查点抑制剂难治性癌症的市场准入与报销15.1 15.1The United States 美国15.2 15.2EU4 and the UK 欧盟四国与英国15.3 15.3Japan 日本15.4 15.4Summary and comparison of Market Access and Pricing Policy Developments in 2025 2025年市场准入与定价政策发展综述及比较15.5 15.5Market Access and Reimbursement of Checkpoint-Inhibitor Refractory Cancer 检查点抑制剂难治性癌症的市场准入与报销16 十六Bibliography 参考文献17 17Checkpoint Inhibitor Refractory Cancer Market Report Methodology 检查点抑制剂难治性癌症市场报告方法论Related Reports 相关报告Checkpoint Inhibitor Clinical Trial Analysis 免疫检查点抑制剂临床试验分析Checkpoint Inhibitor Competitive Landscape – 2026 检查点抑制剂竞争格局 – 2026report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the keyCheckpoint Inhibitor Refractory Cancer companies, including 报告提供了关于管线格局、管线药物概况（包括临床和非临床阶段产品）以及关键 checkpoint 抑制剂难治性癌症公司的全面洞察，包括BeiGene, Apollomics, BCN Biosciences, Phio Pharmaceuticals, Atridia, Jiangsu HengRui Medicine, EMD Serono, Innovent Biologics, Agenus, Eucure Biopharma, PharmaEngine, Vernalis, Array BioPharma, Genentech, Boehringer Ingelheim, Sentinel Oncology, Sierra Oncology, IMPACT Therapeutics, 百济神州、阿波罗生命科技、BCN生物科学、Phio制药公司、Atridia、江苏恒瑞医药、默克雪兰诺、信达生物、Agenus、优科生物制药、药明康德、Vernalis、Array BioPharma、基因泰克、勃林格殷格翰、Sentinel Oncology、Sierra Oncology、IMPACT Therapeutics，and others. 以及其他。Immune Checkpoint Inhibitors Market 免疫检查点抑制剂市场Immune Checkpoint Inhibitors Competitive Landscape and Market Forecast – 2036 免疫检查点抑制剂竞争格局与市场预测——2036年report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key immune checkpoint inhibitors companies, including 本报告提供关于管线格局、管线药物概况（包括临床和非临床阶段产品）以及关键免疫检查点抑制剂公司的全面洞察，包括Regeneron Pharmaceuticals, GlaxoSmithKline, Roche, Boehringer Ingelheim, Xencor, Taiga Biotechnologies, Jiangsu Alphamab Biopharmaceuticals, Dr. Reddy's Laboratories, NATCO Pharma, AstraZeneca, EMD Serono Research & Development Institute, Bristol-Myers Squibb, ImmuneSensor Therapeutics, ImmunityBio, SQZ Biotechnologies, Teon Therapeutics, ALX Oncology, Astellas Pharma, Seagen, Hoffmann-La Roche, NextCure, MiNK Therapeutics, Genmab, BioNTech SE, STORM Therapeutics, Suzhou Kintor Pharmaceutical, Sanofi, Coordination Pharmaceuticals,. 再生元制药、葛兰素史克、罗氏、勃林格殷格翰、Xencor、Taiga Biotechnologies、江苏康宁杰瑞生物制药、雷迪博士实验室、NATCO Pharma、阿斯利康、EMD Serono 研发研究所、百时美施贵宝、ImmuneSensor Therapeutics、ImmunityBio、SQZ Biotechnologies、Teon Therapeutics、ALX Oncology、安斯泰来制药、Seagen、霍夫曼-拉罗氏、NextCure、MiNK Therapeutics、Genmab、BioNTech SE、STORM Therapeutics、苏州开拓药业、赛诺菲、Coordination Pharmaceuticals。and others. 以及其他。PD-(L)1 Inhibitors PD-(L)1抑制剂Market 市场PD-(L)1 Inhibitors PD-(L)1抑制剂Market Insights, Epidemiology, and Market Forecast – 2036 市场洞察、流行病学及市场预测——2036年report deliver an in-depth understanding of the inhibitors, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key PD-(L)1 inhibitorcompanies, including 报告深入阐述了抑制剂、历史及预测流行病学，以及市场趋势、市场驱动因素、市场壁垒和关键的PD-(L)1抑制剂公司，包括FibroGen, EQRx, CStone Pharmaceuticals, Pfizer, Novartis, Arcus Biosciences, Agenus, Tracon Pharmaceuticals, Shanghai Henlius Biotech, Incyte Corporation FibroGen、EQRx、基石药业、辉瑞、诺华、Arcus Biosciences、Agenus、Tracon Pharmaceuticals、上海复宏汉霖生物技术有限公司、Incyte Corporation, ，and others. 以及其他。PD-1 and PD-L1 Inhibitors Competitive Landscape PD-1和PD-L1抑制剂竞争格局PD-1 and PD-L1 Inhibitors Competitive Landscape – 2026 PD-1和PD-L1抑制剂竞争格局——2026年report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key PD-1 and PD-L1 inhibitors companies, including 本报告全面深入分析了研发管线格局、管线药物概况（包括临床和非临床阶段产品），以及关键的PD-1和PD-L1抑制剂相关企业，包括Merck, Laekna Therapeutics, Genentech, Tracon Pharmaceuticals, Celgene, MedImmune, Hangzhou Sumgen Biotech, Lepu Biopharma, Harbour BioMed, Curis, BeiGene, Apollomics, Agenus, Boehringer Ingelheim, Jounce Therapeutics, Seagen, Ascletis Pharma, Secarna Pharmaceuticals GmbH & Co. KG, Arbutus Biopharma. 默克、来凯医药、基因泰克、Tracon Pharmaceuticals、新基生物、MedImmune、杭州尚健生物、乐普生物、和铂医药、Curis、百济神州、云顶新耀、Agenus、勃林格殷格翰、Jounce Therapeutics、Seagen、歌礼制药、Secarna Pharmaceuticals GmbH & Co. KG、Arbutus Biopharma。, and others. ，以及其他。About 关于DelveInsight DelveInsightDelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platformPharmDelve. DelveInsight 是一家领先的商业咨询和市场研究公司，专注于生命科学领域。它通过提供全面的端到端解决方案来帮助制药公司提升业绩。通过我们基于订阅的平台 PharmDelve，您可以轻松获取所有医疗保健和制药市场研究报告。. 。Contact Us 联系我们Shruti Thakur 什鲁蒂·塔库尔[emailprotected] [emailprotected]+14699457679 +14699457679www.delveinsight.com www.delveinsight.comSOURCE DelveInsight Business Research, LLP 来源：DelveInsight Business Research, LLP21 二十一% 百分比more press release views with 更多新闻稿浏览量，通过Request a Demo 申请演示